On November 3, 2016 Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, reported that three abstracts on the Company’s lead product candidate, BPX-501, including an oral presentation by Dr. Neena Kapoor, to review results from a study of pediatric patients with immune deficiencies, were accepted for presentation at the 58th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting (Press release, Bellicum Pharmaceuticals, NOV 3, 2016, View Source;p=RssLanding&cat=news&id=2219233 [SID1234516245]). The Company will also present data highlighting preclinical results from the application of its GoCAR-T and GoTCR technologies in two poster presentations. ASH (Free ASH Whitepaper) 2016 is being held in San Diego, California on December 3-6.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investor/Analyst Luncheon

Bellicum will host an investor and analyst luncheon on Monday, December 5, 2016 at 12:15 PM -1:15 PM PST at the San Diego Marriott Gaslamp Quarter Hotel. Management and investigators Dr. Franco Locatelli (Ospedale Pediatrico Bambino Gesù), Dr. Neena Kapoor (Children’s Hospital of Los Angeles), and Dr. Kris Mahadeo (Montefiore Medical Center) will discuss BPX-501 Phase 2 clinical data in the malignant and non-malignant setting. The luncheon will be webcast live and may be accessed from the News & Events section of the Bellicum website. An archived version of the webcast will be available for replay for at least two weeks following the event.

ASH Presentations on Bellicum Programs

BPX-501:

Oral Presentation: "Outcome of Children with Primary Immune-Deficiencies (PIDs) Enrolled in a Phase I-II Trial Based on the Infusion of BPX-501 Donor T Cells Genetically Modified with a Novel Suicide Gene (Inducible Caspase 9, iC9) After T-Cell Depleted HLA-Haploidentical Allogeneic Stem Cell Transplantation (Haplo-HSCT)"

Abstract Number: 72
Session Name: 732.Clinical Allogeneic Transplantation: Results: Predicting Outcome
Date: Saturday, December 3, 2016
Session Time: 7:30 AM – 9:00 AM PST
Presentation Time: 8:45 AM PST

Poster Presentation: "T-Cell Depleted HLA-Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (Haplo-HSCT) Followed by Donor Lymphocyte Infusion with T Cells Transduced with the Inducible Caspase 9 (iC9) Suicide Gene in Children with Hematological Malignancies"

Abstract Number: 4683
Session Name: 732.Clinical Allogeneic Transplantation: Results: Poster III
Date: Monday, December 5, 2016
Presentation Time: 6:00 PM – 8:00 PM PST

Poster Presentation: "Clinical Outcome and Immune Recovery after Adoptive Infusion of BPX-501 Cells (Donor T Cells Transduced with iC9 Suicide Gene) in Children with Hemoglobinopathies and Diamond-Blackfan Anemia Given a/b T-Cell Depleted HLA-Haploidentical Stem Cell Transplantation (HSCT)"

Abstract Number: 2286
Session Name: 732.Clinical Allogeneic Transplantation: Results: Poster I
Date: Saturday, December 3, 2016
Presentation Time: 5:30 PM – 7:30 PM PST

CAR-T Program: (CD123 CARs)

Poster Presentation: "Inducible MyD88/CD40 (iMC) Costimulation Provides Ligand-Dependent Tumor Eradication by CD123-Specific Chimeric Antigen Receptor T Cells"

Abstract Number: 4551
Session Name: 703.Adoptive Immunotherapy: Poster III
Date: Monday, December 5, 2016
Presentation Time: 6:00 PM – 8:00 PM PST

TCR Program: (PRAME and Bob-1 TCRs)

Poster Presentation: "Inducible MyD88/CD40 (iMC) Enhances Proliferation and Survival of Tumor-Specific TCR-Modified T Cells and Improves Anti-Tumor Efficacy in Myeloma"

Abstract Number: 4550
Session Name: 703.Adoptive Immunotherapy: Poster III
Date: Monday, December 5, 2016
Presentation Time: 6:00 PM – 8:00 PM PST